Reata Pharmaceuticals - RETA Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Reata Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RETA shares.
View RETA analyst ratings or view top-rated stocks.

5 brokers have issued 12-month target prices for Reata Pharmaceuticals' stock. Their RETA share price forecasts range from $40.00 to $115.00. On average, they predict the company's stock price to reach $66.67 in the next twelve months. This suggests a possible upside of 34.7% from the stock's current price.
View analysts price targets for RETA or view top-rated stocks among Wall Street analysts.

Reata Pharmaceuticals' stock was trading at $37.99 at the beginning of the year. Since then, RETA shares have increased by 30.3% and is now trading at $49.50.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our RETA earnings forecast.

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) released its earnings results on Tuesday, November, 8th. The company reported ($2.16) EPS for the quarter, topping the consensus estimate of ($2.35) by $0.19. The business earned $0.54 million during the quarter, compared to the consensus estimate of $1.43 million. Reata Pharmaceuticals had a negative trailing twelve-month return on equity of 322.32% and a negative net margin of 9,897.91%.

10 employees have rated Reata Pharmaceuticals Chief Executive Officer Warren Huff on Glassdoor.com. Warren Huff has an approval rating of 92% among the company's employees. This puts Warren Huff in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Reata Pharmaceuticals investors own include Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Synlogic (SYBX), NVIDIA (NVDA), Basic Energy Services (BAS), Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO) and Archrock (AROC).

(RETA) raised $60 million in an initial public offering (IPO) on Thursday, May 26th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO.

Reata Pharmaceuticals trades on the NASDAQ under the ticker symbol "RETA."

Reata Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.16%), Woodstock Corp (0.04%), Bank of Hawaii (0.03%), HighMark Wealth Management LLC (0.03%), ProShare Advisors LLC (0.02%) and Zurcher Kantonalbank Zurich Cantonalbank (0.01%). Insiders that own company stock include Colin John Meyer, Elaine Castellanos, James Warren Huff and Michael D Wortley.
View institutional ownership trends.

Shares of RETA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RETA stock can currently be purchased for approximately $49.50.

Reata Pharmaceuticals (NASDAQ:RETA) has a market capitalization of $1.81 billion and generates $11.49 million in revenue each year. The company earns $-297,390,000.00 in net income (profit) each year or ($8.56) on an earnings per share basis.

The company employs 346 workers across the globe.

Reata Pharmaceuticals' mailing address is 5320 LEGACY DRIVE, PLANO TX, 75024. The official website for the company is www.reatapharma.com. The company can be reached via phone at (972) 865-2219 or via email at ir@reatapharma.com.